Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase: Implication for atherosclerosis
- 1 December 2003
- journal article
- editorial
- Published by Elsevier in Biochemical Pharmacology
- Vol. 66 (11) , 2069-2073
- https://doi.org/10.1016/s0006-2952(03)00559-8
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteinsJournal of Lipid Research, 2003
- Peroxisome proliferator-activated receptor-α activation and high-density lipoprotein metabolismThe American Journal of Cardiology, 2001
- Ppars, metabolic disease and atherosclerosisPharmacological Research, 2001
- HDLassociated PAF‐AH reduces endothelial adhesiveness in apoE−/−miceThe FASEB Journal, 2000
- Cellular Source(s) of Platelet-Activating-Factor Acetylhydrolase Activity in PlasmaBiochemical and Biophysical Research Communications, 1999
- Apolipoprotein B-100 Conformation and Particle Surface Charge in Human LDL Subspecies: Implication for LDL Receptor InteractionBiochemistry, 1998
- PAF-acetylhydrolase activity on Lp(a) before and during Cu2+-induced oxidative modification in vitroAtherosclerosis, 1996
- Enhanced Association of Platelet-activating Factor Acetylhydrolase with Lipoprotein (a) in Comparison with Low Density LipoproteinJournal of Biological Chemistry, 1995
- PAF-Degrading Acetylhydrolase Is Preferentially Associated With Dense LDL and VHDL-1 in Human PlasmaArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Receptor-Mediated Control of Cholesterol MetabolismScience, 1976